Transferring Phosphorus Containing Group (e.g., Kineases, Etc.(2.7)) Patents (Class 435/194)
  • Patent number: 10844430
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing 5-Chloro-2-methyl-4-isothiazolin-3-one in sequencing reactions, and in particular, sequencing reactions where deoxynucleoside triphosphates comprising a 3?-O position capped by a disulfide-based 3?-terminator group are used. In one embodiment, the deoxynucleoside triphosphates comprise a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 24, 2020
    Assignee: Qiagen Sciences, LLC
    Inventors: Luisa Andruzzi, Jimmy Adediran, Timothy Pelletier, Austin Ricker, Angela DeLucia, Ben McNally, Dona Hevroni, Mong Sano Marma, John Andrew Sheridan
  • Patent number: 10822420
    Abstract: The present invention provides a non-human animal in which a DNA comprising an hp7 sequence-encoding DNA and a poly A addition signal-encoding DNA added on the 3? side of a DNA encoding an arbitrary foreign gene is inserted in the same reading frame as that of an arbitrary target gene present on the genome of the non-human animal.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 3, 2020
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Koichi Jishage, Otoya Ueda
  • Patent number: 10792340
    Abstract: Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 6, 2020
    Assignee: KONKUK UNIVERSITY GLOCAL INDUSTRY-ACADEMIC COLLABORATION FOUNDATION
    Inventors: Yeong Min Park, In Duk Jung, Seung Jun Lee
  • Patent number: 10787669
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: September 29, 2020
    Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Patent number: 10689688
    Abstract: Methods and systems for detecting chemical and biological agents using oligonucleotide aptamers. A sensor includes a detection aptamer that has a binding domain for the chemical or biological agent, and is bound to fibers of a textile such as a patch or article of clothing. The detection aptamer can be stabilized and enhanced through a stabilization agent such as trehalose or through binding to a nanoparticle which is then bound to the fiber. Binding of the chemical and biological agent of interest to the detection aptamer can be reported to the user or wearer of the textile in a variety of ways, including visually and electrically.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 23, 2020
    Assignee: SRC, Inc.
    Inventor: Adam J. Lowe
  • Patent number: 10683537
    Abstract: Provided herein are mutant polymerase enzymes resistant to inhibitors encountered in Polymerase Chain Reactions (PCR). Also provided are nucleic acids or constructs encoding isolated polypeptides having polymerase activity. Also provided are kits useful for PCR containing isolated polypeptides having polymerase activity or isolated nucleic acids encoding such.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: June 16, 2020
    Assignee: DNA Polymerase Technology, Inc.
    Inventors: Milko B. Kermekchiev, Zhian Zhang
  • Patent number: 10676724
    Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having lower systematic error as compared to a reference polymerase. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered properties.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 9, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Peter Vander Horn, Daniel Mazur, Theo Nikiforov, Mindy Landes, Eileen Tozer
  • Patent number: 10669320
    Abstract: Provided herein are compositions and methods for the treatment of cancer by activating the spindle assembly checkpoint (SAC) in cells. In particular, dimerized Mps1 and Spc105/KNL1 constructs are provided as tunable activators of SAC, allowing for control of chromosome segregation accuracy and prevention of aneuploidies that are common in cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 2, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ajit P. Joglekar, Pavithra Aravamudhan
  • Patent number: 10655187
    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 19, 2020
    Assignee: GENCURIX INC.
    Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho
  • Patent number: 10655161
    Abstract: Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 19, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Chen-Hsiung Yeh
  • Patent number: 10638168
    Abstract: A method, computer system, and a computer program product for detecting a minimum viable display resolution is provided. The present invention may include measuring a first quality indicator of a received video file in an original resolution of the received video file. The present invention may then include measuring a second quality indicator of the received video file in a newest resolution of the received video file, wherein the newest resolution of the received video file is a lower resolution relative to the original resolution of the received video file. The present invention may further include, in response to determining that the measured second quality indicator of the newest resolution does not meet a threshold associated with the measured first quality indicator of the original resolution, discarding the newest resolution of the received video file and storing at least one viable display resolution of the received video file.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 28, 2020
    Assignee: International Business Machines Corporation
    Inventors: Jack E. Dunning, Thomas J. Latham, Jordan R. Cain
  • Patent number: 10633641
    Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragment thereof are provided that allow for nucleic acid amplification. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates for use in various downstream processes. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered catalytic properties. In some aspects, the disclosure provides modified polymerases having enhanced catalytic properties as compared to a reference polymerase.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 28, 2020
    Assignee: Life Technologies Corporation
    Inventors: Peter Vander Horn, Theo Nikiforov, Guobin Luo, Mindy Landes, Daniel Mazur, Eileen Tozer, Tommie Lloyd Lincecum
  • Patent number: 10604746
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 31, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Patent number: 10501813
    Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: December 10, 2019
    Assignees: HOKKAIDO MITSUI CHEMICALS INC., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA
    Inventors: Homare Tabata, Hiroshi Minami, Hideki Niimi, Isao Kitajima, Tomohiro Ueno, Shiroh Hayashi, Masashi Mori
  • Patent number: 10465175
    Abstract: Provided are a recombinant microorganism including a genetic modification that increases a pyruvate, phosphate dikinase activity, a method of producing cellulose using the same, and a method of producing a microorganism having enhanced cellulose productivity.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 5, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hongsoon Rhee, Jinkyu Kang, Jinhwan Park, Dongsik Yang
  • Patent number: 10450605
    Abstract: A method for determining the sequence of a target nucleic acid, including steps of contacting a target nucleic acid with a polymerase to sequentially remove nucleotide triphosphates from the target nucleic acid, wherein the nucleotide triphosphates that are removed have a variety of different base moieties; and distinguishing the different base moieties for the nucleotide triphosphates that are removed. Also provided is a apparatus including a nanopore positioned in a fluid impermeable barrier to form a passage through which a nucleotide triphosphate can pass from a first fluid reservoir to a second fluid reservoir, and a reaction mix in the first fluid reservoir that includes a polymerase, target nucleic acid having two strands, and pyrophosphorolytic concentration of pyrophosphate.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 22, 2019
    Assignee: ILLUMINA CAMBRIDGE LIMITED
    Inventor: Wouter Meuleman
  • Patent number: 10427162
    Abstract: The present disclosure provides systems, devices and methods associates with processing and analyzing samples for molecular diagnostics. The system may process samples using assay cartridges including sample preparation modules and PCR modules. The system may include thermal cycler modules and optics modules to detect the specific nucleic acid sequences in the samples.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 1, 2019
    Assignee: QuanDx Inc.
    Inventors: Xiaojun Lei, Yuan Yuan, Qian Xu, Paul Fleming, Ronan Hayes, Brian Lewis, Bruce Richardson
  • Patent number: 10392671
    Abstract: A method of examining a water supply for microbial contamination involves contacting a water supply with a novel reagent having high specificity for a Legionella microbial species, wherein said reagent does not cross-react, or minimally cross-reacts, with a microbial species other than Legionella. The method further involves detecting, or measuring, a contaminating concentration of a Legionella species in the water supply. Useful reagents comprise at least one nucleotide sequence primer comprising a primer sequence selected from SEQ ID NO: 3-10 or a combination of such primer sequences. The increased specificity of such reagents permits more sensitive detection of microbial contamination.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 27, 2019
    Assignee: Dow Global Technologies LLC
    Inventors: Paul O. Schook, Bei Yin
  • Patent number: 10358670
    Abstract: A method for the production of nucleic acid encoding a target protein. The method comprises (a) providing an array of RNA or DNA molecules including one or more encoding the target protein; (b) generating a target protein from the array to form RNA-protein or DNA-protein complexes in which the RNA or DNA molecule is non-covalently or covalently bound to the complex; (c) separating the complexes into compartments wherein most or all of the compartments contain no more than one complex; (d) subjecting the complexes to reaction conditions which allow target protein activity; and (e) selecting nucleic acid encoding the target protein on the basis of the activity associated therewith, wherein when the complex is a DNA-protein complex in which the DNA is non-covalently bound, step b) is performed in the absence of separate compartments for each complex.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: July 23, 2019
    Assignee: THERMO FISHER SCIENTIFIC BALTICS UAB
    Inventors: Arvydas Janulaitis, Remigijus Skirgaila, Dangira Siksniene
  • Patent number: 10336804
    Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: July 2, 2019
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Tong Zhang, Charles L. Sentman
  • Patent number: 10336785
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 2, 2019
    Assignee: Qiagen Sciences, LLC
    Inventors: Mong Sano Marma, Jerzy Olejnik, Ilia Korboukh
  • Patent number: 10301346
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 28, 2019
    Assignee: Qiagen Sciences, LLC
    Inventors: Mong Sano Marma, Jerzy Olejnik, Ilia Korboukh
  • Patent number: 10287349
    Abstract: In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like. Indeed, the new methodology described herein represents a breakthrough by leveraging a full range of combinatorial amino acid replacements, in multiple positions simultaneously, in order to generate modified membrane-spanning proteins.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 14, 2019
    Assignee: ABILITA BIO, INC.
    Inventor: Mauro Mileni
  • Patent number: 10273539
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 30, 2019
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Mong Sano Marma, Jerzy Olejnik
  • Patent number: 10246750
    Abstract: The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: April 2, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • Patent number: 10246498
    Abstract: Non-FRET-based fusion protein reporter molecules are provided that can be used to monitor histone modifications in living cells. Transgenic animals, particularly non-human mammals, whose genomes comprise an expression cassette encoding a non-FRET-based fusion protein reporter, are also provided. Methods of using the fusion reporter molecules for diagnosing histone-modification-associated disorders and to identify candidate pharmaceutical agents that effect histone modification in cells and tissues are also provided.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 2, 2019
    Assignee: The Johns Hopkins University
    Inventors: Hans Tomas Bjornsson, Harry Dietz
  • Patent number: 10240195
    Abstract: This disclosure provides systems and methods for attaching nanopore-detectable tags to nucleotides. The disclosure also provides methods for sequencing nucleic acids using the disclosed tagged nucleotides.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: March 26, 2019
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, GENIA TECHNOLOGIES, INC.
    Inventors: Carl W. Fuller, Shiv Kumar, Jingyue Ju, Randall Davis, Roger Chen
  • Patent number: 10221442
    Abstract: This disclosure provides methods and compositions for sample processing, particularly for sequencing applications. Included within this disclosure are bead compositions, such as diverse libraries of beads attached to large numbers of oligonucleotides containing barcodes. Often, the beads provides herein are degradable. For example, they may contain disulfide bonds that are susceptible to reducing agents. The methods provided herein include methods of making libraries of barcoded beads as well as methods of combining the beads with a sample, such as by using a microfluidic device.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: March 5, 2019
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 10207240
    Abstract: Methods and devices are provided for manipulating droplets on a support using surface tension properties, moving the droplets along a predetermined path and merging two droplets together enabling a number of chemical reactions. Disclosed are methods for controlling the droplets volumes. Disclosed are methods and devices for synthesizing at least one oligonucleotide having a predefined sequence. Disclosed are methods and devices for synthesizing and/or assembling at least one polynucleotide product having a predefined sequence from a plurality of different oligonucleotides having a predefined sequence.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: February 19, 2019
    Assignee: Gen9, Inc.
    Inventors: Joseph Jacobson, Larry Li-Yang Chu, Senthil Ramu
  • Patent number: 10144972
    Abstract: A composition for hot-start reverse transcription reaction and a composition for reverse transcription PCR are disclosed. The composition is obtained by adding pyrophosphate and pyrophosphatase to an aqueous solution containing reaction buffer solution, MgCl2, four kinds of dNTPs, and reverse transcription polymerase in a single reaction tube. The composition for hot-start reverse transcription reaction is obtained by freezing or drying the composition. The composition show increased stability and long-term storage stability. Also, disclosed is a composition that additionally includes DNA polymerase, and, thus, enables a hot-start reverse transcription reaction and a PCR reaction to be sequentially performed. A method for amplifying a nucleic acid by using the composition. The composition of the invention can be conveniently and effectively used in multiplex reverse transcription PCRs or real-time quantitative reverse transcription PCR.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: December 4, 2018
    Assignee: BIONEER CORPORATION
    Inventors: Han Oh Park, Jun Hee Lee, Sora Choi, Hyun Seo Kim
  • Patent number: 10130667
    Abstract: The present invention relates to a vaccine comprising the insertion of three genes, the TAA/ecdCD40L EA1 and CDA, driven by promoters L-plastin/cytosinedeaminase and CMV as a three gene, three transcription unit oncolytic virus as a conditionally replication competent adenoviral vector which replicates only in tumor cells. In these transcription units, the E1A gene of the adenoviral vector as well as the cytosine deaminase gene are under the control of the L-plastin promoter, while the TAA/ecdCD40L transcription unit is under control of a the CMV promoter.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 20, 2018
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10113156
    Abstract: Stabilized reverse transcriptase fusion proteins including a thermostable reverse transcriptase connected to a stabilizer protein are described. Attaching the stabilizer protein to the thermostable reverse transcriptase stabilizes the fusion protein and can aid in its purification, provide increased solubility, allow for longer storage, or allow the fusion protein to be used under more rigorous conditions such as higher temperature. The stabilized reverse transcriptase fusion protein can also include a linker between the stabilizer protein and the thermostable reverse transcriptase. The stabilized reverse transcriptase fusion proteins are suitable for use in nucleic acid amplification methods such as the reverse transcription polymerase chain reaction and other applications involving cDNA synthesis.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: October 30, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alan M. Lambowitz, Sabine Mohr, Georg Mohr, Eman Ghanem
  • Patent number: 10093985
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 9, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 10081799
    Abstract: This disclosure provides, among other things, a composition comprising: comprising a fusion protein comprising: (a) a DNA polymerase; and (b) a heterologous sequence-specific DNA binding domain. A method for copying a DNA template, as well as a kit for performing the same, are also described.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: September 25, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Pei-Chung Hsieh, Luo Sun, Thomas C. Evans, Jr., Theodore B. Davis, Andrew Gardner
  • Patent number: 10047356
    Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: August 14, 2018
    Assignee: NOVELLUSDX LTD.
    Inventors: Yoram Altschuler, Gabi Tarcic
  • Patent number: 10041051
    Abstract: This disclosure provides, among other things, a composition comprising: comprising a fusion protein comprising: (a) a DNA polymerase; and (b) a heterologous sequence-specific DNA binding domain. A method for copying a DNA template, as well as a kit for performing the same, are also described.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 7, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Pei-Chung Hsieh, Luo Sun, Thomas C. Evans, Jr., Theodore B. Davis, Andrew Gardner
  • Patent number: 10036001
    Abstract: The embodiments described herein pertain to cells, and methods for preparing cells, that can be used as biocatalysts by altering enzymes that compete for a substrate or product of a pathway of interest such that the targeted enzyme is sensitive to a site-specific protease, which protease is expressed but relocated in the cell to a site where it is not in contact with the targeted enzyme in the intact cell. Upon cell lysis, the protease contacts the target enzyme, which is then inactivated by protease cleavage.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 31, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, GreenLight Biosciences, Inc.
    Inventor: James R. Swartz
  • Patent number: 10023902
    Abstract: Disclosed are methods of detecting enzymatic activity on a fluorophore-labeled substrate using by monitoring the fluorescence lifetime of the fluorophore.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: July 17, 2018
    Inventors: Laurie Louise Parker, Joseph Maria Kumar Irudayarsaj, Andrew M. Lipchik, Nur Pradani Damayanti
  • Patent number: 9957573
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 1, 2018
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 9944933
    Abstract: Compositions and methods for modifying genetic material are provided. One embodiment provides aptamers capable of binding to a site-specific DNA binding moiety to facilitate the exchange of homologous genetic information between a donor molecule and the desired target locus (aptamer-guided gene targeting or AGT). One embodiment provides an oligonucleotide containing a aptamer, preferably a DNA aptamer at the 5? end. The oligonucleotide also contains a region of homology, also referred to as donor DNA, to a desired nucleic acid, locus, or gene. The DNA binding moiety can be a nucleic acid, a protein, or a complex of proteins. In a preferred embodiment the DNA binding moiety is a homing endonuclease that cuts DNA to facilitate the modification of the DNA by the donor DNA.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: April 17, 2018
    Assignee: Georgia Tech Research Corporation
    Inventors: Francesca Storici, Patrick Ruff
  • Patent number: 9932567
    Abstract: A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 3, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Yan Xu, Jennifer Ong, Shengxi Guan, Nicole Nichols
  • Patent number: 9896671
    Abstract: The technology provided herein relates to novel variants of DNA-Polymerases exhibiting high termo-stability as well as a strong strand displacement activity; to nucleic acid molecules encoding said DNA-Polymerases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions comprising at least one of the DNA-Polymerases; and methods for using such enzymes in DNA sequencing and/or DNA amplification processes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 20, 2018
    Assignee: BIORON GmbH
    Inventors: Konstantin Ignatov, Vladimir Kramarov
  • Patent number: 9868945
    Abstract: In some embodiments, the disclosure relates generally to methods as well as related compositions, systems, kits and apparatus comprising linking proteins to target compounds and/or to locations of interest using tethers. For example, the tether can be used to link the protein to a target compound, for example, to link an enzyme to a substrate. Similarly, the tether can be used to link the protein at or near a desired location on a surface. In one group of embodiments, the tether includes a polynucleotide and the target compound or location on the surface includes another polynucleotide that is capable of hybridizing to the tether. In such embodiments, the tether can be used to link the protein to the target compound or location using nucleic acid hybridization.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: January 16, 2018
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: John Davidson, Theo Nikiforov, Guobin Luo
  • Patent number: 9797004
    Abstract: The invention provides methods and compositions for detecting and/or quantifying vector backbone in a nucleic acid preparation comprising a polynucleotide of interest using amplification assays that amplify a junction located between the polynucleotide of interest and the vector backbone, under conditions whereby amplification can occur, wherein the junction comprises a recognition site for a nuclease, and detecting the absence of an amplification product, whereby the absence of the amplification product indicates low or no vector backbone and/or quantifying the amount of amplification product to determine the amount of vector backbone in the nucleic acid preparation.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: October 24, 2017
    Assignee: Syngenta Participations AG
    Inventors: Chengkun He, Chunyang Fan, John Ke, Heng Zhong, Doug Russell
  • Patent number: 9771565
    Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: September 26, 2017
    Assignee: Life Technologies Corporation
    Inventors: Jun Lee, Robert Jason Potter
  • Patent number: 9739779
    Abstract: The present invention provides a method for screening compounds for their ability to inhibit autophosphorylation of Janus kinase 3 in the absence of any additional substrate. The present invention also provides a method for screening compounds that bind to Janus kinase 3 domains other than the kinase domain, to identify synthetic or natural compounds including biomolecules, that modulate Janus kinase 3 activity. This invention also describes a multi-component screening kit composed of purified recombinant Janus kinase 3 proteins and recombinant phosphorylated Janus kinase 3 fusion proteins including, one or more phosphorylated or non-phosphorylated domain-deleted Janus kinase 3 fusion proteins.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 22, 2017
    Inventors: Narendra Kumar, Jayshree Mishra
  • Patent number: 9714268
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: July 25, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Eldar Zehorai
  • Patent number: 9683251
    Abstract: A method for the production of nucleic acid encoding a target protein. The method comprises (a) providing an array of RNA or DNA molecules including one or more encoding the target protein; (b) generating a target protein from the array to form RNA-protein or DNA-protein complexes in which the RNA or DNA molecule is non-covalently or covalently bound to the complex; (c) separating the complexes into compartments wherein most or all of the compartments contain no more than one complex; (d) subjecting the complexes to reaction conditions which allow target protein activity; and (e) selecting nucleic acid encoding the target protein on the basis of the activity associated therewith, wherein when the complex is a DNA-protein complex in which the DNA is non-covalently bound, step b) is performed in the absence of separate compartments for each complex.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 20, 2017
    Assignee: Thermo Fisher Scientific Baltics UAB
    Inventors: Arvydas Janulaitis, Remigijus Skirgaila, Dangira Siksniene
  • Patent number: RE46683
    Abstract: Disclosed are methods and kits applicable to sequencing methods, such as Sanger dideoxy sequencing methods. The methods and kits disclosed utilize a cationically charged nucleic acid terminator in combination with a discriminatory polymerase.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 23, 2018
    Assignee: Applied Biosystems, LLC
    Inventors: Barnett Rosenblum, Steven Menchen, Shaheer Khan, Paul Kenney
  • Patent number: RE47684
    Abstract: Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is —CHY—C(CH3)2Z, Y and Z are each independently —H or —OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 5, 2019
    Assignee: TMS CO., LTD.
    Inventors: Honda Kazuo, Terumasa Hashimoto, Keita Shibata, Keiko Hasegawa, Keiji Hasumi